Last patient last visit in randomized, double-blind, SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease is scheduled for early June 2024 ROCHESTER, N.Y., May 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of Semaphorin 4D (SEMA4D),…
Wed, 28 Aug 2024 07:34:00 GMT Research and development expenses, net, were US$0.51 million in the second quarter of 2024, compared to US$0.46 million in the same quarter in 2023. The increase was primarily due to higher ...
Tue, 27 Aug 2024 13:01:00 GMT This press release contains a financial outlook within the meaning of applicable Canadian securities laws. The financial outlook has been prepared by management of the Company to provide an ...
Tue, 13 Aug 2024 17:00:00 GMT Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.
Tue, 13 Aug 2024 12:12:00 GMT Guerrilla RF, Inc. (OTCQX: GUER), a leading provider of state-of-the-art RF and microwave semiconductors, today announced results for the quarter ended June 30, 2024. This press release features ...
Wed, 07 Aug 2024 23:00:00 GMT YETI reports ... the prior year quarter. See "Product Recall Reserves" below for additional information on the impact of the product recalls referenced throughout this press release.
